Axial Biotherapeutics to Participate in 5th Annual BMO Private Company Showcase
WALTHAM, Mass.--(BUSINESS WIRE)--Oct 11, 2019--
Axial Biotherapeutics, a biotechnology company dedicated to building a unique class of gut-targeted programs for neurodegenerative diseases and neurodevelopmental disorders, today announced that the company will present at the 5 th Annual BMO Private Company Showcase on Friday, October 18, 2019 at 9:40 AM ET.
About Axial Biotherapeutics
Axial Biotherapeutics is a clinical stage biopharmaceutical company pioneering novel science focused on the interaction between the brain and the gut to mitigate the causes and symptoms of CNS and other gut-derived diseases. The Company has built a pipeline of novel small-molecules and live biotherapeutics with lead programs to address the significant unmet patient needs associated with Parkinson’s Disease and Autism Spectrum Disorder.
View source version on businesswire.com:https://www.businesswire.com/news/home/20191011005018/en/
Stern Investor Relations, Inc.
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: MENTAL HEALTH HEALTH CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY
SOURCE: Axial Biotherapeutics
Copyright Business Wire 2019.
PUB: 10/11/2019 08:01 AM/DISC: 10/11/2019 08:01 AM